Skip to content

Investigation of the Effect of Oral Consumption of Cress Seed on Sexual Dysfunction in Female Patients with Multiple Sclerosis

Investigation of the effects of oral consumption of Lepidium sativum L. seed on sexual dysfunction in female patients with multiple sclerosis: A randomized double-blind placebo-control clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160913029802N5
Enrollment
68
Registered
2026-04-22
Start date
2026-06-05
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Multiple Sclerosis. Condition 2: Sexual dysfunction associated with multiple sclerosis. Multiple sclerosis Other sexual disorders

Interventions

Intervention 1: Intervention group: Participants receiving the oral product containing powdered cress seeds prepared in the Pharmacognosy and Pharmaceutics laboratories of the Faculty of Pharmacy, Sar

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults aged 18 years and older diagnosed with multiple sclerosis, according to the 2015 McDonald criteria, with an EDSS score of less than 5.5. Sexually active in the past six months and experiencing sexual problems, with an MSISQ-19 score above 27.

Exclusion criteria

Exclusion criteria: Severe depression assessed using the HADS questionnaire (score of 11 or higher) Hypothyroidism Untreated anemia History of seizures Diabetes History of bulimia nervosa or anorexia nervosa Presence of a known severe psychiatric disorder Pregnancy or breastfeeding Exposure to major crises, such as the death of close relatives, in the past six months Genitourinary environmental problems

Design outcomes

Primary

MeasureTime frame
Sexual dysfunction. Timepoint: At baseline, and at 6 and 12 weeks after the start of treatment. Method of measurement: The 19-item Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19).

Secondary

MeasureTime frame
Multiple Sclerosis Quality Of Life. Timepoint: At baseline, and at 6 and 12 weeks after initiation of treatment. Method of measurement: Multiple Sclerosis Quality Of Life 54(MSQOL-54) score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonireh Ghazaeian

Mazandaran University of Medical Sciences

ghazaeianm@gmail.com+98 11 3354 3082

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026